Comparative Pharmacology
Head-to-head clinical analysis: PROCAN SR versus PROCAPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAN SR versus PROCAPAN.
PROCAN SR vs PROCAPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procainamide is a class Ia antiarrhythmic agent that blocks sodium channels, reducing myocardial excitability and conduction velocity, and prolonging the refractory period.
Procapan is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, increasing their concentrations in the synaptic cleft.
Oral: 50 mg/kg/day divided every 6 hours; typical adult dose: 250-500 mg every 6 hours. For sustained-release (Procan SR): 500-1000 mg every 6 hours.
Adults: 10 mg orally three times daily; maximum 40 mg/day.
None Documented
None Documented
Procainamide: 2.5-4.7 hours (normal renal function); NAPA: 6-8 hours. In renal impairment, half-life prolonged up to 10-20 hours for procainamide and 40+ hours for NAPA.
Terminal half-life: 6.5 hours (range 4-9 h) in normal renal function; prolonged in renal impairment (up to 15 h in ESRD)
Renal: 50-60% as unchanged procainamide; hepatic metabolism to N-acetylprocainamide (NAPA) which is also renally excreted; total renal excretion of procainamide + NAPA accounts for ~85% of dose; remainder fecal (<5%).
Renal: 70-80% unchanged; fecal: 10-20% as metabolites; biliary: <5%
Category C
Category C
Class Ia Antiarrhythmic
Class Ia Antiarrhythmic